Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.
Kaczmar J, Mehra R
The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer
Ther Adv Respir Dis (2015) 9:236-41.
Research over the last decade has determined that the gene rearrangement involving the anaplastic lymphoma kinase (ALK) gene is an oncogenic driver in approximately 5% of patients with non-small cell lung carcinoma (NSCLC). This review describes the discovery of the ALK translocation, development of ALK directed therapy, and acquired resistance to ALK directed therapy with a focus on the clinical data and efficacy of the most recently approved ALK inhibitor, ceritinib.
Publication Date: 2015-10-01.
Last updated on Saturday, August 22, 2020